← Back to Clinical Trials
Recruiting NCT07561138

NCT07561138 Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07561138
Status Recruiting
Phase
Sponsor Kalliopi Anna Poulia
Condition End-stage Liver Disease
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2026-01-08
Primary Completion 2028-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Diet with even protein distribution plus exercise programDiet with skewed protein distribution plus exercise programStandard dietary and physical activity advice

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2026-01-08 with a primary completion date of 2028-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C) on nutritional status, body composition and functional status in patients awaiting liver transplantation.

Eligibility Criteria

Inclusion Criteria: * End-stage liver disease, diagnosed by transient elastography (FibroScan) or imaging-based evaluation with compatible clinical picture * Referred for liver transplantation and evaluated to have a high likelihood of being listed, according to primary hepatologist assessment, or already listed for liver transplantation * No prior formal dietary advice Exclusion Criteria: * Age \< 18 years old * Estimated waiting time for liver transplantation \< 3 months * Estimated life expectancy \< 3 months * Chronic kidney disease requiring protein restriction * Exercise contraindicated (e.g., active or recent variceal bleeding, severe grade of hepatic encephalopathy, refractory ascites, etc.) * Unstable or severe psychiatric disorder * Pregnancy or lactation * Inability to provide written informed consent

Contact & Investigator

Central Contact

Kalliopi Anna Poulia

✉ lpoulia@aua.gr

📞 +30 2105294668

Frequently Asked Questions

Who can join the NCT07561138 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying End-stage Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07561138 currently recruiting?

Yes, NCT07561138 is actively recruiting participants. Contact the research team at lpoulia@aua.gr for enrollment information.

Where is the NCT07561138 trial being conducted?

This trial is being conducted at Athens, Greece, Athens, Greece.

Who is sponsoring the NCT07561138 clinical trial?

NCT07561138 is sponsored by Kalliopi Anna Poulia. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology